The article’s full text is unavailable because access to the page was denied, so its specific findings cannot be independently summarised. Based on the headline, it reports on a study suggesting that GLP-1 medicines may reduce long-term sickness absence, potentially affecting both public health and labour-market participation.

GLP-1 drugs are commonly used to treat type 2 diabetes and obesity, and may improve health conditions that can contribute to prolonged absence from work. However, the study’s methods, size, results and limitations are not provided in the accessible text, so no firm conclusions or figures can be stated.